Scinai Immunotherapeutics Ltd. (SCNI) NASDAQ
0.76
+0.305(+66.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Scinai Immunotherapeutics Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
May 11, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Amir Reichman | Chief Executive Officer & Director | 387,000 | 1976 |
| Uri Ben-Or | Chief Financial Officer | 136,000 | 1970 |
| Elad Mark | Chief Operating Officer | 196,000 | 1982 |
| Naama Adi Hen | Head of Quality Asurance | 0 | N/A |
| Gal Ron | Head of HR | 0 | N/A |
| Merav Kamensky | Head of Quality Control & GMP Analytics | 0 | N/A |
| Tehila Sonnenfeld | Head of Manufacturing | 0 | N/A |
Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
